Olivier Loeillot on mergers and acquisitions
From 🎞 #LiveWithChaudhrey S06E067 with Repligen Corporation CEO Olivier Loeillot March 6th 2025 · · RSK Life Science Media
“We like to say we've got two or three real features in our DNA. One of them is innovation. The second one is M&A. We've been managing to grow very fast because we've been good at acquiring companies under the M&A scheme of Repligen, which is trying to be exclusive as much as possible because we understand some of these very innovative technologies maybe earlier than others. Are we going to do more? Absolutely.”
On , Olivier Loeillot, President, Chief Executive Officer & Director at REPLIGEN CORP, spoke about mergers and acquisitions during 🎞 #LiveWithChaudhrey S06E067 with Repligen Corporation CEO Olivier Loeillot March 6th 2025 on RSK Life Science Media.
About Olivier Loeillot
In a March 2025 interview, Repligen CEO Olivier Loeillot discussed the company's recent acquisition of 908 Devices, describing it as part of a multi-year effort to expand its process analytical technology (PAT) offerings. Loeillot stated that the acquisition would give Repligen access to "four very exclusive, very differentiating PAT technologies" and enable the company to expand its implementation of PAT in manufacturing systems. He characterized M&A as part of Repligen's "DNA" and said the company plans to continue acquiring companies, focusing on exclusive, innovative technologies. Loeillot described 2024 as "a pretty tough year for the industry" and noted that Repligen faced additional challenges, including the loss of OEM partners for its protein business. He said the company still managed about 3% growth excluding COVID in 2024. Looking ahead, Loeillot expressed optimism about 2025, citing a mix of breakthrough innovation, focus on new modalities, and market differentiation. He noted that Repligen had increased its R&D budget to around 6.5% of total sales and was investing more in its commercial organization. Loeillot also emphasized the need for bioprocessing companies to adopt PAT technologies to support pharma companies' use of artificial intelligence, stating that "AI is only useful if you collect data, and data is collected via PAT."